Skip to content

Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin

Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02612233
Acronym
DUPRO
Enrollment
81
Registered
2015-11-23
Start date
2013-09-30
Completion date
2016-07-31
Last updated
2016-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hand Osteoarthritis

Keywords

Pain

Brief summary

Osteoarthritis is the most common form of arthritis worldwide. Specifically, osteoarthritis of the hands affects millions of people and is a major cause of hand disability and pain. Despite this, there are currently no treatments that delay or halt the development of osteoarthritis. Pain is one of the major symptoms of osteoarthritis and pain management is an important factor to consider in the treatment of this condition. Treatments for pain in osteoarthritis consists of local injections, anti-inflammatory gels or painkillers such as paracetamol. However, most people with osteoarthritis still have pain despite these treatments.

Detailed description

Recent scientific studies have suggested that people with hand osteoarthritis not only feel pain in their hand joints, they also appear to have increased signals in their brain pain processing pathways. At St George's, University of London, the investigators have been conducting studies to find out which brain regions are activated in subjects with hand osteoarthritis. The investigators have found that certain brain regions (thalamus, insula, cingulate and somatosensory cortex) are activated during painful tasks in patients with hand osteoarthritis but not in healthy people. In this study the investigators will establish whether drugs that inhibit pain processing pathways in the brain can help. Patients who are still having pain despite their usual painkillers will be randomly divided into 3 groups: one group will receive a placebo, the other 2 groups will receive one of two different drugs, duloxetine or pregabalin. Participants will be assessed using questionnaires and a brain scan (functional MRI) before and after 13 weeks of taking the tablets. This study will help us to understand the ways in which people feel pain in osteoarthritis. If our trial proves successful,drugs that dampen central pain pathways could be used in combination with local pain-relieving drugs to improve treatment and reduce disability in patients with hand osteoarthritis.

Interventions

DRUGPregabalin or Duloxetine or Placebo

This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm

Sponsors

Rosetrees Trust
CollaboratorOTHER
St George's, University of London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Participants fulfilling the American College of Rheumatology (ACR) criteria for the diagnosis of hand osteoarthritis * Participants with hand osteoarthritis presenting to rheumatology outpatient clinics and primary care. * Participants will be right or left handed * Male or female * Age between 40 and 75 * Participants will be on usual care for hand osteoarthritis including paracetamol and/or non-steroidal anti-inflammatory drugs

Exclusion criteria

* Participants with other rheumatological diagnoses e.g. rheumatoid arthritis * Current or planned pregnancy * Contraindications to duloxetine or pregabalin * History of depression * Recent surgery * Previous use of duloxetine and/or pregabalin

Design outcomes

Primary

MeasureTime frameDescription
Australian/Canadian Hand Osteoarthritis Index score (AUSCAN)12 weeksThe AUSCAN measures pain and hand function. Differences between baseline AUSCAN and after treatment will be recorded for each participant to assess for improvement in AUSCAN pain and function score after the trial intervention.

Secondary

MeasureTime frameDescription
Brain magnetic resonance imaging (MRI)Baseline and 12 weeks after treatmentChanges between baseline MRI and post-treatment after 12 weeks of intervention will be measured using functional neuroimaging to assess pain center activation before and after intervention.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026